3-Aminophenyl boric acid | 141645-97-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Aminophenyl boric acid
• 英文别名: 3-Aminophenylboric acid；(3-aminophenoxy)boronic acid
• CAS: 141645-97-8
• 化学式: C₆H₈BNO₃
• 分子量: 152.945
• InChiKey: UTHULKKJYXJZLV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.38
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  75.7
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-bromo-8-(2,6-dichlorobenzoylamino)quinoline 、 3-Aminophenyl boric acid 生成 3-(3-Aminophenyl)-8-(2,6-dichlorobenzoylamino)quinoline
  参考文献：
  名称：

  Quinoline compounds as H.sup.+ -ATPases

  摘要：

  这项发明涉及一种喹啉化合物，其化学式为：##STR1## 其中R.sup.1是吡啶基或芳基，每个基可能被适当的取代基取代，A是--COHN--或--NHCO--，n是0或1的整数，而##STR2## 是一个化学式为：##STR3## 的基团，其中R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7如定义，以及其药学上可接受的盐，制备方法，包含相同化合物的药物组合物，以及用于预防和/或治疗由人类或动物骨骼异常代谢引起的骨病的方法。

  公开号：

  US06008230A1

文献信息

• Benzothiazole derivatives
  申请人：BASF Aktiengesellschaft Ludwigshafen, Germany

  公开号：US20030153568A1

  公开（公告）日：2003-08-14

  The present invention is directed to a compound of formula (I), 1 racemic-diastereomeric mixtures thereof, optical isomers thereof, prodrugs thereof, isotopes thereof or pharmaceutically-acceptable salts of said compound, isomers, prodrugs and isotopes, wherein the variables are defined herein. The compounds of this invention are useful as inhibitors of serine/threonine and tyrosine kinases. In particular, compounds of this invention are useful as inhibitors of tyrosine kinases that are important in hyperproliferative diseases, especially in cancer and in the process of angiogenesis.

  本发明涉及一种化合物，其化学式为(I)，其1立体混合物、光学异构体、前药、同位素或该化合物、异构体、前药和同位素的药用可接受盐，其中变量在此处定义。本发明的化合物可用作丝氨酸/苏氨酸激酶的抑制剂。具体而言，本发明的化合物可用作重要的酪氨酸激酶抑制剂，在增殖过程中尤其在癌症和血管生成过程中重要。
• Amine compounds, their production and use
  申请人：——

  公开号：US20040077867A1

  公开（公告）日：2004-04-22

  A compound of the formula: 1 wherein Ar is an aromatic ring assembly group which may be substituted or a fused aromatic group which may be substituted; X is (i) a bond, (ii) —S—, —SO— or —SO 2 —, (iii) C 1-6 alkylene, C 2-6 alkenylene or C 2-6 alkynylene, etc., (iv) —CO—O— or (v) —(CH 2 )p-X 1 —, —(CH 2 )p-X 1 —CH 2 )q-, —(CH 2 )r-CO—X 1 —, —SO 2 —NR 8 — or —(CH 2 )r-SO 2 —NR 8 — wherein X 1 is O or NR 8 , R 8 is H, a hydrocarbon group which may be substituted or an acyl, p is 0 to 5, q is 1 to 5, p+q is 1 to 5, and r is 1 to 4; Y is a divalent C 1-6 aliphatic hydrocarbon group optionally containing O or S, which may be substituted; R 1 and R 2 each is H or a lower alkyl which may be substituted, or R 1 and R 2 form a N-containing heterocyclic ring which may be substituted; Ring A is a benzene ring which may be further substituted; and Ring B is a 4- to 8-membered ring which may be further substituted, or a salt thereof has the effect of inhibiting amyloid-&bgr; protein production and/or secretion and is useful as a pharmaceutical composition for preventing and/or treating the neurodegenerative disease, etc.

  化合物的公式为1，其中Ar是芳香环组装基团，可以是取代的或融合的芳香族基团，X是(i)键，(ii) -S-, -SO-或-SO2-, (iii) C1-6烷基，C2-6烯基或C2-6炔基等，(iv) -CO-O-或(v) -(CH2)p-X1-，-(CH2)p-X1-CH2)q-，-(CH2)r-CO-X1-，-SO2-NR8-或-(CH2)r-SO2-NR8-其中X1是O或NR8，R8是H，可以是取代的碳氢基团或酰基，p为0至5，q为1至5，p+q为1至5，r为1至4；Y是二价的C1-6脂肪烃基团，可以包含O或S，可以是取代的；R1和R2分别是H或可以取代的低碳烷基，或R1和R2形成一个可以取代的含氮杂环；环A是苯环，可以进一步取代；环B是4-至8成员环，可以进一步取代，或其盐具有抑制淀粉样-β蛋白产生和/或分泌的作用，并且作为预防和/或治疗神经退行性疾病的药物组成物有用。
• Furopyridine, thienopyridine pyrrolopyridine useful in controlling
  申请人：Abbott Laboratories

  公开号：US06001849A1

  公开（公告）日：1999-12-14

  Novel heterocyclic ether compounds having the formula: ##STR1## wherein A, m, R, X, Y.sup.1, Y.sup.2 and Y.sup.3 are specifically defined, which are useful in selectively controlling chemical synaptic transmission; therapeutically-effective pharmaceutical compositions thereof; and use of said compositions to selectively control synaptic transmission in mammals.

  具有以下式子的新异杂环醚化合物：##STR1## 其中A、m、R、X、Y.sup.1、Y.sup.2和Y.sup.3具有特定定义，可用于有选择地控制化学突触传递；其治疗有效的药物组合物；以及使用该组合物有选择地控制哺乳动物的突触传递。
• Amine compounds, their production and use as amyloid-&bgr; production inhibitors
  申请人：Takeda Chemical Industries, Ltd.

  公开号：US06310107B1

  公开（公告）日：2001-10-30

  A compound of the formula: wherein Ar is an aromatic ring assembly group which may be substituted or a fused aromatic group which may be substituted; X is (i) a bond, (ii) —S—, —SO— or —SO2—, (iii) C1-6 alkylene, C2-6 alkenylene or C2-6 alkynylene, etc., (iv) —CO—O— or (v) —(CH2)p-X1—, —(CH2)p-X1— (CH2)q-, —(CH2)r-CO—X1—, —SO2—NR8— or —(CH2)r-SO2—NR8— wherein X1 is O or NR8, R8 is H, a hydrocarbon group which may be substituted or an acyl, p is 0 to 5, q is 1 to 5, p+q is 1 to 5, and r is 1 to 4; Y is a divalent C1-6 aliphatic hydrocarbon group optionally containing O or S, which may be substituted; R1 and R2 each is H or a lower alkyl which may be substituted, or R1 and R2 form a N-containing heterocyclic ring which may be substituted; Ring A is a benzene ring which may be further substituted; and Ring B is a 4- to 8-membered ring which may be further substituted, or a salt thereof has the effect of inhibiting amyloid-&bgr; protein production and/or secretion and is useful as a pharmaceutical composition for preventing and/or treating the neurodegenerative disease, etc.

  该化合物的化学式为: 其中Ar是一个芳香环组成的群，可以被取代或一个融合的芳香基团，可以被取代; X是(i)一个键，(ii) -S-, -SO-或-SO2-, (iii) C1-6烷基，C2-6烯基或C2-6炔基等，(iv) -CO-O-或(v) -(CH2)p-X1-, -(CH2)p-X1-(CH2)q-, -(CH2)r-CO-X1-, -SO2-NR8-或-(CH2)r-SO2-NR8-其中X1是O或NR8，R8是H，一个可以被取代的碳氢化合物基团或一个酰基，p为0至5，q为1至5，p+q为1至5，r为1至4; Y是一个二价的C1-6脂肪烃基团，可选含有O或S，可以被取代; R1和R2各自是H或可以被取代的低烷基，或R1和R2形成一个可以被取代的含N杂环；环A是一个苯环，可以进一步被取代; 环B是一个4至8成员环，可以进一步被取代，或其盐具有抑制淀粉样蛋白β的产生和/或分泌的作用，并且可用作预防和/或治疗神经退行性疾病等的药物组合物。
• Quinoline compounds as H.sup.+ -ATPases
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US06008230A1

  公开（公告）日：1999-12-28

  This invention relates to a quinoline compound of the formula: ##STR1## wherein R.sup.1 is a pyridyl group or aryl, each of which may be substituted with suitable substituent(s), A is --COHN-- or --NHCO--, n is an integer of 0 or 1, and ##STR2## is a group of the formula: ##STR3## In which R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined, and pharmaceutically acceptable salt thereof, to processes for preparation thereof, to a pharmaceutical composition comprising the same, and to a method for the prevention and/or the treatment of bone diseases caused by abnormal bone metabolism in human being or animals.

  这项发明涉及一种喹啉化合物，其化学式为：##STR1## 其中R.sup.1是吡啶基或芳基，每个基可能被适当的取代基取代，A是--COHN--或--NHCO--，n是0或1的整数，而##STR2## 是一个化学式为：##STR3## 的基团，其中R.sup.2、R.sup.3、R.sup.4、R.sup.5、R.sup.6和R.sup.7如定义，以及其药学上可接受的盐，制备方法，包含相同化合物的药物组合物，以及用于预防和/或治疗由人类或动物骨骼异常代谢引起的骨病的方法。